Last reviewed: July 2, 2026
Last updated: July 2, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Many people ask whether Ozempic is FDA-approved for weight loss, and the answer involves an important distinction. Ozempic (semaglutide) is FDA-approved specifically for managing type 2 diabetes, while Wegovy—a higher-dose formulation of the same active compound—received FDA clearance in 2021 for chronic weight management in adults with obesity or overweight status plus weight-related conditions. Both medications work through the same GLP-1 receptor pathway, but their regulatory approvals target different health outcomes.
Ozempic vs. Wegovy: Understanding the FDA Approval Difference
Ozempic and Wegovy contain identical active ingredients—semaglutide—but carry separate FDA approvals for distinct therapeutic uses. Ozempic was approved by the FDA in September 2017 as an injectable medication for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise. Wegovy received FDA approval on June 4, 2021, specifically for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related health condition such as hypertension, type 2 diabetes, or cardiovascular disease.
The dosing regimens also differ between the two formulations. Ozempic typically starts at 0.25 mg weekly and may be titrated up to 1 mg weekly for diabetes management. Wegovy follows a longer titration schedule beginning at 0.25 mg weekly and escalating over 16 weeks to a maintenance dose of 2.4 mg weekly. This higher maintenance dose in Wegovy correlates with its specific indication for weight loss rather than glucose control, though both medications activate the same GLP-1 receptors in the brain and gut.
How Semaglutide Produces Weight Loss Through GLP-1 Receptor Activation
Semaglutide's weight loss mechanism operates through multiple pathways in the body's appetite and satiety regulatory centers. The medication binds to GLP-1 receptors located in the hypothalamus and other brain regions that control hunger signals, leading to reduced appetite and increased feelings of fullness. Additionally, semaglutide slows gastric emptying—the rate at which food moves from the stomach into the small intestine—which prolongs satiety and decreases the urge to eat between meals.
Clinical trials demonstrate significant weight reduction with semaglutide therapy across patient populations. The STEP 1 trial, published in the New England Journal of Medicine, showed that adults receiving the 2.4 mg weekly dose of semaglutide achieved an average weight loss of 15.3% of their baseline body weight over 68 weeks, compared to 2.6% in the placebo group. These results established the clinical foundation for Wegovy's FDA approval and remain among the most substantial weight loss outcomes observed with GLP-1 receptor agonist monotherapy.
Why Compounded Semaglutide Offers Personalized Access Without Insurance Requirements
PlexusDx provides compounded semaglutide injection manufactured by licensed 503A compounding pharmacies, delivering the same active pharmaceutical ingredient as brand-name formulations at a significantly lower starting cost of $149 per month. Compounded medications are created on-demand by state-licensed pharmacists following FDA-established standards for strength, purity, and quality, allowing healthcare providers to offer tailored dosing schedules that match individual patient needs and responses.
The compounding approach enables PlexusDx to serve all 50 states without requiring insurance coverage, eliminating prior authorization delays and monthly approval requests that often plague brand-name GLP-1 therapy. Patients maintain flexibility to adjust their dose upward as their treatment progresses, with the pricing tier remaining stable—reflecting PlexusDx's commitment that doses may increase while monthly costs do not. Additionally, semaglutide therapy through PlexusDx qualifies for HSA and FSA reimbursement when combined with a documented weight loss treatment plan.
Genetic Testing Can Identify Your Optimal GLP-1 Peptide Response
Not every person responds identically to semaglutide, and genetic variation in appetite-regulating peptide pathways influences treatment outcomes. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after month one) that analyzes 14 metabolic pathways, 49 peptides, and 150+ genetic insights including variants in the GLP1R gene (rs6923761), GIPR receptor (rs1800437), and other key regulators of satiety and energy balance. This peptide-pathway genetic assessment helps PlexusDx providers personalize medication selection, dosing strategies, and potential combination therapies.
Patients carrying certain genetic variants may show enhanced or reduced responsiveness to GLP-1 monotherapy, which genetic testing can predict before committing to extended treatment. For example, individuals with specific FTO (rs9939609) or MC4R (rs17782313) variants may benefit from dual-peptide approaches such as PlexusDx's GLP-Squared Injection, which combines semaglutide and tirzepatide for amplified appetite suppression. Genetic insight allows PlexusDx providers to match each patient with the medication protocol most likely to produce meaningful, sustained weight loss aligned with their biology.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Ozempic actually approved by the FDA for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes management, not weight loss. Wegovy, a higher-dose semaglutide formulation, is the FDA-cleared medication specifically for chronic weight management. However, Ozempic is sometimes prescribed off-label for weight loss. PlexusDx offers compounded semaglutide injection starting at $149/month as a regulated, accessible alternative to both options.
When did Wegovy receive FDA approval for weight loss?
Wegovy (semaglutide 2.4 mg) received FDA approval on June 4, 2021, for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. Clinical trials showed participants lost an average of 15.3% of baseline body weight over 68 weeks, establishing strong evidence for its indication. This approval followed Ozempic's 2017 diabetes authorization by four years.
How much does PlexusDx compounded semaglutide cost per month?
PlexusDx compounded semaglutide injection starts at $149 per month across all commitment tiers, with the pricing principle that your dose may increase but your monthly price will not. No insurance is required, and treatment qualifies for HSA and FSA reimbursement. PlexusDx serves all 50 states with medications from licensed 503A compounding pharmacies.
Are compounded semaglutide medications as safe as brand-name versions?
Yes. PlexusDx compounded medications are manufactured by licensed 503A compounding pharmacies following FDA standards for strength, purity, and quality. Compounded semaglutide contains the same active pharmaceutical ingredient as Ozempic and Wegovy. However, compounded medications are not FDA-approved; they are FDA-regulated. Your PlexusDx provider will monitor you for standard GLP-1 side effects including nausea, vomiting, and pancreatitis risk.
Should I get genetic testing to determine if semaglutide will work for me?
PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 14 pathways and 150+ genetic insights to predict your response to semaglutide and identify whether dual-peptide therapies like GLP-Squared might produce better outcomes. Testing identifies variants in GLP1R, GIPR, FTO, and MC4R that influence appetite regulation, allowing your provider to personalize your protocol before investing months in a single medication.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Navigating Your Journey: How Many Months Does It Take for Ozempic to Work for Sustainable Health?
Understanding Ozempic: What Are Some of the Side Effects of Taking Ozempic?